NCT03327597Active, not recruitingPhase 2
Iceland Screens, Treats or Prevents Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 30 Sept 2025
Brief summary (registry, in English)
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80761 (actual)
- First submitted
- 19 Oct 2017
- Start date
- 1 Sept 2016
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- University of Iceland
- Diseases
- Multiple myeloma
- NCT number
- NCT03327597
- EU CT number
- 2024-519353-11-00
- EudraCT number
- 2017-004785-10
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 80761
- From 1 Sept 2016 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior multiple myeloma
Other illness
- Lymphoproliferative disease
Lab values
- M-protein \>30 g/L or involved:uninvolved serum FLC ratio \>100
- Individuals with prior history of MGUS will be offered to be randomized into either moderate or intensive clinical follow-up (arms 2 or 3).
Other
- Amyloidosis
Who the study is looking for
- Born 1975 or earlier
- With registered address in Iceland on November 1st 2016
Age in the registry: 40 years to 64 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Landspitali Coordinator of this site? Confirm its status | Reykjavik | Iceland | Not yet recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.